ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Study of TV-1106 in Growth Hormone-Deficient Adults

ClinicalTrials.gov ID: NCT02410343

Public ClinicalTrials.gov record NCT02410343. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 6:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy, Safety and Tolerability Study of TV-1106 in Growth Hormone-Deficient Adults Who Are Not Current Users of rhGH Treatment

Study identification

NCT ID
NCT02410343
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Enrollment
14 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • TV-1106 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 29, 2015
Primary completion
Dec 30, 2015
Completion
Dec 30, 2015
Last update posted
Jan 23, 2022

2015

United States locations

U.S. sites
25
U.S. states
10
U.S. cities
18
Facility City State ZIP Site status
Teva Investigational Site 13102 Artesia California 90701
Teva Investigational Site 13127 Fountain Valley California 33155-6541
Teva Investigational Site 13126 Fountain Valley California 92708
Teva Investigational Site 13103 Miami Florida 33126
Teva Investigational Site 13118 Miami Florida 33130
Teva Investigational Site 13123 Miami Florida 33145
Teva Investigational Site 13492 Miami Florida 33155-6541
Teva Investigational Site 13114 Miami Lakes Florida 33016
Teva Investigational Site 13100 Pembroke Pines Florida 33024
Teva Investigational Site 13121 West Palm Beach Florida 33401
Teva Investigational Site 13104 Chicago Illinois 60612
Teva Investigational Site 13124 Evansville Indiana 47714
Teva Investigational Site 13101 Detroit Michigan 48202
Teva Investigational Site 13112 Henderson Nevada 89052
Teva Investigational Site 13113 Las Vegas Nevada 89148
Teva Investigational Site 13109 Brooklyn New York 11235
Teva Investigational Site 13494 New York New York 10016
Teva Investigational Site 13106 New York New York 10032
Teva Investigational Site 13096 Asheville North Carolina 28803
Teva Investigational Site 13108 Pittsburgh Pennsylvania 15212
Teva Investigational Site 13110 Arlington Texas 76014
Teva Investigational Site 13125 Dallas Texas 75218
Teva Investigational Site 13097 Houston Texas 77079
Teva Investigational Site 13107 Houston Texas 77084
Teva Investigational Site 13120 Houston Texas 77090

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02410343, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 23, 2022 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02410343 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →